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Caveolin-1 is an integral membrane protein primarily responsible for the formation of membrane
structures known as caveolae. Caveolae are specialized lipid rafts involved in protein trafﬁcking,
cholesterol homeostasis, and a number of signaling functions. It has been demonstrated that caveolin-1
suppresses HIV-1 protein expression. We found that co-transfecting cells with HIV-1 and caveolin-1
constructs, results in a marked decrease in the level of HIV-1 transcription relative to cells transfected
with HIV-1 DNA alone. Correspondingly, reduction of endogenous caveolin-1 expression by siRNA-
mediated silencing resulted in an enhancement of HIV-1 replication. Further, we observed a loss of
caveolin-mediated suppression of HIV-1 transcription in promoter studies with reporters containing
mutations in the NF-kB binding site. Our analysis of the posttranslational modiﬁcation status of the p65
subunit of NF-kB demonstrates hypoacetylation of p65 in the presence of caveolin-1. Since hypoace-
tylated p65 has been shown to inhibit transcription, we conclude that caveolin-1 inhibits HIV-1
transcription through a NF-kB-dependent mechanism.
& 2012 Elsevier Inc. All rights reserved.Introduction
Human Immunodeﬁciency Virus-1 (HIV-1) is a human retro-
virus that infects CD4þ T lymphocytes and myeloid cells. Our
studies and those of others have demonstrated that HIV-1 biology
is critically dependent upon cholesterol (Chertova et al., 2006;
Graham et al., 2003; Liao et al., 2001). HIV infection of T cells
enhances expression of genes encoding proteins involved in
cholesterol biosynthesis (Zheng et al., 2003; Zheng et al., 2001).
Conversely, inhibiting the cholesterol biosynthetic pathways
during HIV-1 infection suppresses replication of the virus (del
Real et al., 2004). Cholesterol-enriched cellular membrane micro-
domains known as lipid rafts are the sites for HIV-1 entry and
egress (Liao et al., 2001; Nguyen and Hildreth, 2000). The
treatment of cells with cyclodextrins has a potent effect on the
integrity of lipid rafts (Graham et al., 2003; Liao et al., 2001).
Notably, HIV-1 susceptible cells treated with cholesterol-seques-
tering cyclodextrins are less susceptible to HIV-1 infection
(Graham et al., 2003; Liao et al., 2001; Liao et al., 2003).
Additionally, disruption of lipid rafts reduces virion infectivity
and release from cholesterol-enriched cells (Booth et al., 2006;ll rights reserved.
ildreth).Gould et al., 2003; Jouvenet et al., 2006; Liao et al., 2003; Nguyen
et al., 2003; Welsch et al., 2007). The dependence on cholesterol
for multiple aspects of HIV-1 biology suggests that cellular
mechanisms that regulate cholesterol homeostasis may modulate
HIV-1 replication (del Real et al., 2004; Graham et al., 2003;
Liao et al., 2001; Liao et al., 2003; Mujawar et al., 2006; Waheed
et al., 2007).
In addition to cholesterol and glycosphingolipids, lipid rafts
are also comprised of proteins (Hooper, 1999; Lajoie and Nabi.
One such protein, caveolin-1, is a cholesterol-binding protein that
is responsible for the formation of caveolae, specialized mem-
brane structures that represent a distinct class of lipid rafts
(Kurzchalia and Parton, 1999). Caveolins are a family of proteins
that consist of four isoforms including: caveolin1a, -1b, -2
and 3. These proteins are expressed in most nucleated cells,
excluding T-lymphocytes (Arakawa et al., 2000; Glenney and
Soppet, 1992; Matveev et al., 1999; Razani et al., 2002). Caveolae
are 60–100 nm ﬂask-like invaginations in the plasma membrane.
Caveolae, like lipid rafts in general, are enriched in cholesterol,
sphingolipids, and other raft-speciﬁc constituents (Dobrowsky,
2000; Fielding and Fielding, 2000; Frank et al., 2006; Harder and
Simons, 1997; Hooper, 1999; Kurzchalia and Parton, 1999; Quest
et al., 2004). Caveolae function as scaffolds for signaling proteins
and as vesicles for intracellular cholesterol transport (Arakawa
et al., 2000; Fielding and Fielding, 1997; Frank et al., 2006; Ikonen,
G.E. Simmons Jr. et al. / Virology 432 (2012) 110–119 1111997). Caveolin-1 has been reported to function as an inhibitor of
signaling molecules such as endothelial nitric oxide synthase (eNOS)
and is known to modulate processes such as chronic inﬂammation
(Razani et al., 2001; Vargas et al., 2002; Yeh et al., 2004). Several
studies have demonstrated that caveolin-1 regulates inﬂammation
through the p38 MAPK and NF-kB pathways (Garrean et al., 2006;
Lv et al.; Pontrelli et al., 2006; Wang et al., 2006). Another group
reported that caveolin-1 null mice (cav-1 -/-) displayed a signiﬁcant
decrease in NF-kB activity after LPS stimulation, indicating that
caveolin-1 plays a critical role in some antimicrobial defense
mechanisms (Garrean et al., 2006).
Ectopic expression of caveolin-1 has been shown to suppress
the replication of HIV-1 (Llano et al., 2002). However, the
molecular mechanism of this inhibition of the HIV-1 life cycle
by caveolin-1 remains largely undeﬁned (Carter et al., 2010).
Inhibitory effects of caveolin-1 appeared to be HIV-1 speciﬁc, as
caveolin had little or no effect on other classes of viruses (Llano
et al., 2002). Notably, caveolin-1 did not suppress virus species
that replicated in the cytoplasm. In another study, HIV-1 infection
of macrophages appeared to correlate with an induction of
caveolin-1 expression in a HIV-Tat dependent manner (Lin et al.,
2010). HIV-1 infection has been shown to lead to induction of a
number of signal transduction pathways, some of which involve
caveolin-1 (Bennasser et al., 2001; Cheng et al., 2009; Yang et al.).
In the present study, we determined that the inhibitory effect
of caveolin-1 on HIV-1 replication is mediated through modula-
tion of the NF-kB-dependent inﬂammatory pathway. Speciﬁcally,
we demonstrate that caveolin-1 inhibition of HIV-1-LTR promoter
activity is mediated via suppression of NF-kB acetylation.cav-1vector
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Fig. 1. Overexpression of caveolin-1 suppresses HIV-1 protein expression and virus
clone pYU-2 and caveolin-1expression construct or vector control. Cells and supernata
analyzed by Western blot analysis with an anti-Gag mAb (upper panels). We conﬁrmed e
used b-tubulin as a loading control (bottom panel). (B) Virus particle production was a
Graph represents 3 independent experiments done in replicates with S.E.M., p valueo
speciﬁc or control siRNAs, then 48 h later transfected with pYU-2. Protein expression wResults
Caveolin-1 expression suppresses HIV-1 production
Studies have shown that expression of caveolin-1 creates a
restrictive cellular environment for HIV-1 replication (Lin et al.,
2010; Llano et al., 2002). More recently, it has been shown that
HIV-1 infection induces caveolin-1 expression in macrophages
(Lin et al., 2010). These ﬁndings have intriguing implications and
they may in part explain the persistence of HIV-1 infection in
monocytic cells in the absence of the cytopathology observed in
lymphocytes. We set out to determine the step of the HIV-1 life-
cycle impacted by caveolin-1. We ﬁrst veriﬁed that caveolin-1
expression decreased virus production as previously reported. To
that end, 293 T cells were transfected with caveolin-1 or empty
vector along with HIV-1 molecular clone, pYU-2. Forty-eight
hours post-transfection, virus production was measured using
Western blot analysis and HIV-1 p24 ELISA. We observed a
signiﬁcant reduction in cell-associated virus proteins (Fig. 1A)
and virus present in cell culture supernatant from cells over-
expressing caveolin-1 (Fig. 1B). These observations conﬁrmed that
caveolin expression was associated with lower HIV replication. To
further explore this relationship, 293 T cells were sequentially
transfected, ﬁrst with control or caveolin-1 speciﬁc siRNAs and
then with HIV-1 molecular clones. Cells transfected with caveo-
lin-1 siRNA exhibited a reduction in caveolin-1 expression when
compared to control cells (Fig. 1C). This reduction of caveleolin-1
expression was sufﬁcient to enhance the level of cell-associated
viral proteins when compared to control cells (Fig. 1C). This effectIB: anti-Gag
IB: anti-cav-1
IB: anti-actin
IB: anti-p24 Gag
p55
p41
release in 293 T cells. Here, 293 T cells were co-transfected with HIV-1 molecular
nts were harvested 48 h post-transfection. (A) HIV-1 Gag protein expression was
xpression of caveolin-1 by probing with a polyclonal antibody (middle panels) and
ssessed by performing HIV-1 p24 ELISA using supernatants from transfected cells.
0.05. (C) 293 T cells were ﬁrst transfected with one of 2 independent caveolin-1
as analyzed after an additional 24 h.
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indicate that caveolin-1 expression restricts HIV-1 viral replica-
tion in 293 T cells as previously reported.
Caveolin-mediated HIV-1 suppression is independent of modulation
of cellular cholesterol
Caveolin-1 proteins bind and transport cholesterol within cells
(Fielding and Fielding, 1997; Ikonen and Parton, 2000). Caveolae
regulate factors that are involved cholesterol homeostasis, such as
SR-BI and ABCA1 (Bist et al., 1997; Frank et al., 2006; Lin et al.,
2010; Lin et al., 2009; Wong et al., 2006; Yeh et al., 2004), and
some of these affect HIV-1 replication (Morrow et al., 2010;
Mujawar et al., 2006; Mujawar et al., 2010). Therefore, we asked
whether caveolin-mediated inhibition of HIV-1 involved disrup-
tions in cholesterol homeostasis, as measured by changes in total
cellular free cholesterol. To test this we ﬁrst transfected 293 T
cells with caveolin-1 or control vectors. Untransfected cells
treated with cholesterol efﬂux inducer, LXR agonist TO-901317,
or cholesterol sequestering agent b-cyclodextrin, served as posi-
tive controls for the assay. Cells were harvested two days post
transfection. The cells were then ﬁxed and stained with ﬁlipin to
label total free cholesterol and subsequently analyzed by ﬂow
cytometry. As expected, treatment of cells with TO-901317 or
b-cyclodextrin reduced the free cholesterol content of cells
(Fig. 2A). However, cells overexpressing caveolin-1 had no detect-
able difference in free cholesterol content when compared to
controls (Fig. 2B). These observations were recapitulated in both
membrane fraction analyses of transfected cells, as well as
ﬂuorescent microscopy (data not shown). These results indicate
that caveolin-1 does not cause signiﬁcant changes in cellular
cholesterol localization or content in our model system.
Transcription of HIV-1 is suppressed in the presence of caveolin-1
While it was known that manipulations of cholesterol content in
HIV-1 susceptible cells have a major effect on virus replication (Liao
et al., 2001; Liao et al., 2003), the effect of caveolin-1 on HIV-1 is still
largely uncharacterized. Because HIV-1 replication involves a num-
ber of essential steps, we thought it necessary to determine at which%
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Fig. 2. Caveolin-1 overexpression in 293 T cells does not cause global changes in free
were stained with ﬂuorescent cholesterol-binding reagent ﬁlipin at 48 h post-transfecti
untransfected cells were treated with conditions that stimulated cholesterol efﬂux (5 uM
1 h), prior to ﬁlipin staining as described in Methods. Cellular free cholesterol content w
lines are control cells that were not stained. (B) Caveolin-1 transfected or control cells
cells. Data for ﬁlipin-stained cell populations are plotted as histograms.replication steps caveolin-1 inhibited HIV-1. Since caveolin-1 is a
membrane protein with roles in signaling events, we wanted to
determine whether the protein affected early steps in virus replica-
tion like transcription, or late steps such as assembly and budding. It
has been shown that HIV-1 Gag expression alone is sufﬁcient to
generate virus-like particles (VLP) that can be released from cells
(Haynes et al., 1991; Rasmussen et al., 1990; Wang et al., 1990). We
utilized a cytomegalovirus (CMV) promoter-driven Gag-GFP plasmid
to examine VLP release from cells overexpressing caveolin-1. Cells
and cell supernatants were collected 48-hours post-transfection in
order to measure the HIV-1 VLP production by p24 ELISA. The total
amount of HIV-1 Gag in the system was measured, (i.e. intracellular
Gag and Gag present in cell supernatants), and those values were
used to calculate the virus particle release efﬁciency (Figure S1).
Virus particle release efﬁciency is the percentage of HIV-1 Gag
released from the cell relative to the total amount of Gag produced
in the system. No differences in release efﬁciency were observed
between experimental conditions. This indicates that overexpres-
sion of caveolin-1 did not alter the ability of virus to exit cells. We
next determined the effect of caveolin overexpression on HIV-LTR
transcription. To test this we co-transfected caveolin or control
plasmids with an HIV-LTR GFP-reporter construct. Flow cytometric
analysis of transfected cells revealed a substantial reduction in
HIV-LTR activity in cells that expressed caveolin (Fig. 3A). Next we
decided to test the speciﬁcity of this caveolin-dependent transcrip-
tional suppression by using GFP reporters with either LTR or CMV
promoters. The CMV promoter is constitutively active in mamma-
lian cells, and therefore an adequate control for global changes in
transcriptional activity in a cell (Fitzsimons et al., 2002). On the
other hand, the HIV-LTR is highly regulated and often requires
cellular activation before maximal activity can be detected (Cheng
et al., 2009; Huang et al., 1994; Kinoshita et al., 1998; Malcolm et al.,
2007; Marzio et al., 2002; Sadowski and Mitchell, 2005; Verhoef
et al., 1999). Each viral promoter construct was co-transfected with
caveolin-1 into 293T cells which were harvested 48 h later for ﬂow
cytometric analysis. The ﬂuorescent signals were quantiﬁed and
plotted in graphs based on the relative mean ﬂuorescence intensity
(MFI). In cells transfected with CMV-Gag-GFP there were no
differences between caveolin-1-transfected and control cells
(Fig. 3B). In contrast, caveolin-1 expression resulted in a substantial%
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as determined by ﬂow cytometry and graphed in a histogram as indicated. Dotted
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Fig. 3. Caveolin-1 suppresses HIV-1 promoter activity. (A) 293 T cells were transfected with caveolin-1-RFP expression construct (ﬁlled histogram) or RFP control vector
(open histogram), along with HIV-1-LTR GFP reporter. HIV-1 LTR GFP signal was measured by ﬂow cytometry 48 h post transfection and data was plotted in a histogram,
where MFI of samples are indicated. (B) 293 T cells were co-transfected with caveolin-1 (stripped) or vector control (black) and either Cytomegalovirus (CMV)—or HIV-1
LTR-promoter driven Gag-GFP plasmids. Cells were harvested 48 h post-transfection and GFP-MFI signal from the individual promoters was analyzed by ﬂow cytometry.
Graphs represent 3 independent experiments done in replicates with S.E.M., p value o0.05.
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antibodies in FACS analysis, we were able to observe inhibition of
HIV-1 protein expression up to 70% in caveolin-1 transfected cells
(data not shown).
We observed caveolin-1-mediated suppression of transcrip-
tion from HIV-1 reporters in our system under basal conditions,
where no stimulus like LPS or TNF-alpha was administered. We
decided to test the ability of caveolin-1 to suppress Tat-activated
HIV transcription. The HIV-1 Tat protein is a potent transactivator
of HIV transcription and provides a robust increase in LTR activity
(Huang et al., 1994; Marzio et al., 2002; Yang et al.). Caveolin-1
was found to suppress both basal and Tat-enhanced transcription
in 293 T cells (Fig. 4A). To conﬁrm that caveolin-1 suppresses
HIV-1 promoter activity in a physiologically relevant system, we
co-transfected THP-1 cells with caveolin-1 expression plasmids
and an HIV-1 reporter. The cells were cultured in the absence or
presence of TNF-alpha and then we measured the activity of the
reporter 12 h post transfection (Fig. 4B). Further, we assessed the
capacity of caveolin-1 to suppress HIV-1 transcription when p65
is overexpressed (Fig. 4C). In these experiments, we were able to
determine that caveolin-1 was capable of suppressing HIV-1
transcription under all conditions. Correspondingly, we observed
an increase in HIV-1 transcription in THP-1 cells that were ﬁrst
transfected with siRNA against caveolin-1 and then infected with
a VSV-G pseudotyped HIV-1 reporter virus (Figure S2). Taken
together our data strongly implicate caveolin-1 as a transcrip-
tional inhibitor of the HIV-1 promoter
Caveolin-1 suppression of HIV-1 replication requires NF-kB
It is well documented that HIV-1 infection induces a number
signaling pathways, including the inﬂammatory pathway
(Herbein and Varin, 2010; Ross et al., 2006). Inﬂammation is a
host defense mechanism against infection and is largely sufﬁcient
to create an inhospitable environment for many pathogens.
However, this is not the case for HIV-1 infections, which induce
inﬂammation and in fact beneﬁt greatly from the activation of the
numerous host transcription factors that are known to mediate
the inﬂammatory response (DeLuca et al., 1999; Montano et al.,
1996; Roulston et al., 1993; Verhoef et al., 1999; Westendorp
et al., 1995). Caveolin-1, on the other hand, has been shown to
suppress inﬂammatory responses (Chidlow and Sessa; Garrean
et al., 2006; Lv et al.; Wang et al., 2006). Since our data indicates
that caveolin-1 speciﬁcally inhibits HIV-1-LTR transcription, wehypothesize that NF-kB could mediate caveolin’s effect on HIV-1
replication. NF-kB binding sites are present in the HIV-1 LTR, and
in cells other than T cells, NF-kB drives the majority of HIV
transcription (DeLuca et al., 1999; Montano et al., 1996; Roulston
et al., 1993; Westendorp et al., 1995). To determine the contribu-
tion NF-kB to inhibition of HIV-1 by caveolin, NF-kB reporters
were co-transfected along with caveolin expression constructs
into 293 T cells. Fourteen hours post-transfection, the cells were
treated with 10 ng/mL of TNF-a for 10 h. After stimulation with
TNF-a, cells were harvested and analyzed by microscopy and ﬂow
cytometry. Microscopy showed that the overall level of the NF-
kB-GFP signal was reduced in caveolin-1 transfected cells (Fig. 5A,
top). We noted a difference in the intensity of RFP signal from
caveolin-1-RFP transfected cells when compared to RFP vector
transfected cells, possibly due to intrinsic differences in protein
stability. Flow cytometry data indicated that NF-kB activity was
suppressed in cells transfected with caveolin-1 (Fig. 5A, lower). To
determine the NF-kB-dependence of caveolin-mediated suppres-
sion of HIV-1 transcription, we next transfected cells with either
wild-type HIV-LTR (wtLTR) reporters or reporter containing point
mutations in the NF-kB binding site (nkLTR). We observed
caveolin-1-dependent suppression of transcription only in cells
transfected with a wild-type LTR. The mutant HIV-1 reporter
(nkLTR) was insensitive to caveolin-1-mediated suppression
(Fig. 5B). To further examine the requirement for NF-kB in
caveolin-mediated suppression, we next employed speciﬁc inhi-
bitors of NF-kB activation in cells transfected with caveolin-1 and
HIV-1 molecular clone pNLENG1. Transfected cells were cultured
in the absence or presence of 50 mg/ml of speciﬁc IkB kinase (IKK)
inhibitor peptide for 18 h. In cells that received the IkB kinase
inhibitor peptide, caveolin-1-mediated suppression was ablated
(Fig. 5C). These observations indicate that caveolin suppresses
HIV-1 expression not by simply inhibiting NF-kB activity but by a
mechanism that requires NF-kB nuclear translocation. Our results
also suggest that NF-kB binding to the HIV-1 promoter is a
required step for caveolin-1-mediated suppression of HIV-1
transcription.
Caveolin-1 decreases the acetylation of NF-kB p65
We have demonstrated that caveolin-1-mediated suppression
of HIV-1 requires NF-kB translocation, but we have not deter-
mined the consequence of that relocation. Our data clearly show
that NF-kB-dependent transcription is reduced when caveolin-1
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Fig. 4. Caveolin-1 suppresses both tat-independent and dependent HIV-1 LTR
transcription. Cells were transfected with caveolin-1DNA and transcriptional
activity from HIV-1 reporters was measured by ﬂow cytometry. (A) 293 T cells
were co-transfected with caveolin-1 (stripped) or empty vector control (black)
along with HIV-1 LTR reporter and -/þHIV-1 Tat. HIV-1-LTR-GFP ﬂuorescence was
measured 24 h post-transfection by ﬂow cytometry. Displayed is the average of
3 independent experiments. (B) THP-1 monocytic cells were transfected with
vector or caveolin along with HIV-1 LTR reporter and treated with 50 ng/ml of
TNF-afor the last 2 h of cell culture before harvest. The GFP signal from the HIV-1-
LTR reporter was measured by ﬂow cytometry. Caveolin-transfected samples were
normalized to control vector transfected counterparts. TNF-a treated samples
were normalized to 1. (C) THP-1 cells were co-transfected with caveolin-1
expression construct or empty vector control along with RelA expression construct
and HIV-1 LTR GFP reporter. All graphs represent at least 2 independent experi-
ments done in replicates with S.E.M., p value o0.05
G.E. Simmons Jr. et al. / Virology 432 (2012) 110–119114is expressed and that nuclear NF-kB is involved. Interestingly,
Chen et al. have described post-translational modiﬁcations at
K310 that could alter NF-kB transcriptional activity. In their work
unacetylated p65 subunit was unable to drive transcription.
Nonetheless, up until this point it was unclear how a normally
positive modulator of HIV-1 transcription was made to suppress
viral replication by caveolin-1. Post-translational modiﬁcation of
p65 is required for optimum transcriptional activity (Chen et al.,
2002; Chen et al., 2005). Acetylation is one such modiﬁcation that
has been described as a molecular switch for transcriptional
activation, providing an additional layer of NF-kB regulation
(Kiernan et al., 2003). Therefore we suspected that caveolin-1overexpression affected the post-translational modiﬁcation of the
p65, making it less transcriptionally active. To test this possibility
in 293 T cells, we ﬁrst co-expressed caveolin-1 with p65-myc, and
then probed for acetylation speciﬁcally at K 310. As predicted, we
observed a signiﬁcant decrease in K 310 acetylation (Figure S3).
These observations indicated that caveolin-1 suppresses p65 K
310 acetylation.
Intriguingly, Kiernan et al. observed that acetylation at resi-
dues 122/123 of p65 has the ability to lower the DNA-binding
capacity of NF-kB. Hence, suppression of p65 acetylation could
result in increased binding of transcriptionally inert p65 to kB,
resulting in reduced expression of NF-kB-responsive genes. In lieu
of having available reagents that can be used to probe for
acetylation of K 122/123, we assessed global acetylation levels
of p65 in the presence of caveolin-1. Here, 293T cells were ﬁrst
co-transfected with p65-myc and caveolin-1 expression con-
structs or vector control. Thirty-six-hours after transfection, we
prepared cell lysates which were subjected to immunoprecipita-
tion of transfected p65 using antibodies directed against the myc-
epitope in overexpressed p65 or acetylated p65 with pan-speciﬁc
anti-acetyl-lysine antibodies. Next, we detected the total amount
of p65 precipitated in each sample with a pan-speciﬁc p65
antibody. We observed a marked reduction in the amount of
p65 in the acetyl-lysine immunoprecipitates of samples over-
expressing caveolin-1 when compared to vector control (Fig. 6A,
lane 8 and 9). However we detected similar amounts of p65 in the
samples immunoprecipitated using anti-myc antibody (Fig. 6A,
lanes 5 and 6). These observations support the hypothesis that
caveolin-1 expression can suppress global acetylation of p65.
To assess if global hypoacetylation of p65 mediated by
caveolin-1 results in differential DNA binding, we performed
electrophoretic mobility shift assays (EMSA). For these studies,
nuclear extracts were prepared from 293 T cells co-transfected
with caveolin-1 and p65-myc expression constructs. We observed
a 3.5-fold enhancement in the level of p65 bound to kB-contain-
ing probes derived from the HIV-1 LTR when comparing nuclear
extracts from caveolin-1 transfected cells to extracts from control
cells (Fig. 6B, compare lanes 7 and 11). The shifted species was
not detected when using an HIV-1 LTR probe with mutated kB
sites (data not shown). This ﬁnding was also independently
veriﬁed by a plate-based transcription factor binding assay
(Figure S4). Increased p65 DNA binding was transfection and
concentration dependent. These ﬁndings indicate that caveolin-1
expression resulted in modiﬁcations of NF-kB that not only
lowered its transcriptional activity, but also increased the DNA-
binding capacity to kB sites. This occurs via combined hypoace-
tylation of NF-kB residues K 310 and K 122/123, which regulate
transcriptional activity and DNA-binding, respectively (Chen
et al., 2002; Kiernan et al., 2003). These observations likely
explain the profound effect of caveolin-1 on HIV-1 replication in
cells that require NF-kB to drive viral transcription. Our model for
caveolin-mediated suppression of HIV-1 showed that caveolin
alters the equilibrium between acetylated and unacetylated forms
of p65 (Fig. 7). This shift increases the pool of p65 that is
transcriptionally inert but capable of DNA binding, thus providing
a mechanism for suppressing NF-kB-dependent transcription.Discussion
It has been several years since the ﬁrst report of caveolin-1-
dependent inhibition of HIV-1 (Llano et al., 2002). During that
time there have been few attempts to identify the mechanism for
caveolin-1 suppression of HIV-1. A recent study demonstrated
that caveolin-1 interacts with HIV-1 envelope proteins (gp41) and
potentially facilitates entry (Hovanessian et al., 2004). A number
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kinase inhibitor peptide, SN50 (50 mg/mL) for 18 h. HIV-1-LTR reporter activity was analyzed by ﬂow cytometry. All data shown represents 3 independent experiments. Graph
represents three independent experiments done in replicates with S.E.M. p value o0.05.
Vector/
RELA
Cav-1/
RELAmock
1 132 3 4 5 6 7 8 9 10 11 12
IB: anti-p65
p65
free probe
Nuclear extract:
Cav-1: - - + - - + - - +
RelA: - + + - + + - + +
IB: anti-p6564
Input
1 2 3 4 5 6 7 8 9
IP: anti-myc IP: anti-Ac-lysine
Fig. 6. Caveolin-1 overexpression decreases total acetylation of p65. 293 T cells were transfected with caveolin-1 and myc-tagged RelA expression constructs as
indicated. (A) Total cells lysates were immunoprecipitated using either anti-myc or anti-acetyl-lysine antibodies and analyzed by and Western blot analysis. Blots were
probed with monoclonal anti-p65 antibodies to determine efﬁcacy of pull-down. (B) Electrophoretic mobility shift assays (EMSA) performed with increasing volumes of
nuclear extracts (0.5–4 uL) from caveolin-1 and RelA transfected 293 T cells. DNA binding was determined using biotinylated-HIV-1-LTR oligonucleotides and
chemiluminescent detection. Replica nuclear extract samples were analyzed for p65 expression by Western blot (lower panel).
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Fig. 7. Model of caveolin-1 mediated suppression of HIV-1 transcription via
hypoacetylation of NF-kB p65 subunit. Expression of caveolin results in
hypoacetylation of p65 resulting in increased binding to DNA while making the
protein transcriptionally inert.
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modulating viral pathogenesis in vivo (Benferhat et al., 2009a;
Benferhat et al., 2009b; Benferhat et al., 2008; Fermin and Garry,
2005; Hovanessian et al., 2004; Huang et al., 2007; Rey-Cuille
et al., 2006; Wang et al., 2010). Based on some of our previous
studies on the role of cholesterol in HIV-1 biology, we initially
suspected that the mechanism of HIV-1 inhibition by caveolin
would be linked to its role as a cholesterol transporter. However,
data from the current study indicated that caveolin’s role in
cholesterol homeostasis was not essential to the mechanism by
which it inhibits HIV-1 replication. Based on the known role of
caveolin in modulation of inﬂammatory responses, we queried
whether altered signal transduction could explain suppression of
HIV-1 by the protein. NF-kB is the prototypical initiator of
inﬂammatory processes in cells and is also one of the major
transcription factors induced during the course of HIV-1 infection.
We hypothesized that caveolin-1 inhibited HIV-1 replication by
suppressing NF-kB-induced transcription.
Our results showed that instead of reducing NF-kB association
with DNA, caveolin expression increased DNA binding of nuclear
NF-kB. Further, mutation of the NF-kB binding site in the HIV-LTR
ablated the suppressive effect of caveolin on HIV transcription.
These results indicated that caveolin-mediated suppression of
HIV-1 required nuclear association of NF-kB and binding to the
LTR. While we were completing our studies, Wang et al. published
a study conﬁrming that caveolin suppressed HIV-1 transcription
through an NF-kB-dependent mechanism (Wang et al., 2011). In
that study, the investigators abrogated caveolin-1 mediated
suppression of HIV-1 by blocking nuclear translocation of NF-kB
with the inhibitor SN50 conﬁrming that NF-kB was necessary for
caveolin-1 mediated suppression of HIV-1 replication. We
extended our observations and those of the study by Wang
et al. by demonstrating that binding of hypoacetylated NF-kB to
the HIV-1 promoter is the speciﬁc mechanism by which caveolin-
1 inhibits HIV-1.
It is possible that cells, such as macrophages, have developed
mechanisms to protect themselves from the cytopathic effects of
HIV-1 infection. Modulation of caveolin-1 levels during the course
of infection may be a host cell response designed to combat HIV-1
replication at the level of viral transcription (Lin et al., 2010). The
detailed steps that are involved in the mechanism are still some-
what unclear, but with the evidence presented in this study it is
clear that caveolin-1-mediated suppression of HIV-1 requires
DNA binding of NF-kB p65. This ﬁnding is similar to a phenom-
enon previously described when unacetylated p65 is present in
the nucleus. In the absence of acetylation, NF-kB p65 suppresses
transcriptional activity, while showing enhanced DNA bindingcapacity. Currently it is unclear how caveolin could affect acet-
ylation of p65. One potential mechanism would be caveolin-
dependent reduction of expression or activity of molecules such
as SIRT-1 or p300, which are responsible for acetylation status of
NF-kB. Investigating the effect of caveolin-1 on these molecules
will be the subject of further studies. Understanding how caveolin
modulates factors that regulate NF-kB p65 function may provide
important new insights into differences in HIV-1 replication in T
cells and macrophages.Materials and methods
Cells and constructs
293 T human embryonic kidney cells were cultured in DMEM
(GIBCO/Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum, 10 mM L-glutamine and 5 mM Hepes and 100U/ml
penicillin and streptomycin (complete DMEM). THP-1 monocytes
were cultured in RPMI (GIBCO/Invitrogen, Carlsbad, CA, Carlsbad,
CA) supplemented with 10% fetal bovine serum, 10 mM L-gluta-
mine, and 5 mM HEPES (complete RPMI). pYU-2 (obtained from
NIH AIDS Research and Reference Reagent Program) is a CCR5-
tropic HIV-1 molecular clone derived from a human brain viral
isolate. Caveolin-1 cDNA was excised from pOTB7 by EcoRI/XhoI
digestion and subcloned into pcDNA3.1þ vector, (pCav1). Caveo-
lin-1-myc-RFP and RFP-myc vectors were kind gifts from Dr.
Robert Nabi (University British Columbia) were made by subclon-
ing caveolin-1 gene into pRFP-N1 vector (Clontech, Mountain View,
CA). NF-kB reporter, Cignal NFkB Reporter (GFP) Kit (CCS-013,
SABioscience). Caveolin-1 silencing experiments were performed
using Silencer select pre-designed caveolin-1 siRNA, 50-GCC-
GUCUAUUCCAUCUAtt30 (Ambion Inc., Foster City, CA). Wild-type
and mutant HIV-1-LTR constructs were cloned into pZsgreen
expression vector (cat. no. 632446, Clontech, Mountain View, CA)
to generate LTR reporters as previously described (Taylor et al.,
2011). The following primers were used to generate HIV-1-LTR and
HIV-1-NF-kB mutant LTR reporters: wtLTR-Zsgreen- 50-TGACATC-
GAGCTTGCTACAAGGGACTTTCCGCTGGGGACTTTCC-30 and nkLTR-
Zsgreen 50-TGACATCGAGCTTGCTACAAGCCACTTTCCGCTGGGGACT-
TTCC-30.
Virus stock
Virus preparation and viral infection. Virus stocks were pre-
pared by transfecting 293 T cells with HIV-1 plasmid DNA using
Lipofectamine 2000 reagent (Invitrogen). VSV-G envelope-pseu-
dotyped virus was produced as previously reported (Zhou et al.,
2005). Culture supernatants were collected 48 h after transfec-
tion, centrifuged at 1000 g to remove cell debris, ﬁltered
through a 0.45-mm-pore-size ﬁlter, and concentrated by ultra-
centrifugation at 100,000 g through a cushion of 20% sucrose in
PBS. The pelleted virus was resuspended in RPMI with 10% FBS,
aliquoted, and stored at 801C. The viral titer was measured by
anti-p24Gag ELISA.
Transfection
Transfections were carried out by utilizing the Lipofectamine
2000 (Invitrogen, Carlsbad, CA) protocol for plasmid DNA trans-
fection and Oligofectamine (Invitrogen, Carlsbad, CA, Carlsbad,
CA) for siRNA transfection per manufacturer’s instructions. Pre-
liminary transfections utilized pCav1 and pYU-2. siRNA transfec-
tions were done in a sequential manner to maximize the effect of
caveolin-1 knockdown on HIV-1 replication. Cells were trans-
fected with siRNA as previously described, and incubated for 24 h.
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additional 48 h before they were harvested. To monitor transfec-
tion efﬁciency, speciﬁc siRNAs were co-transfected along with a
ﬂuorescent-tagged control siRNA. To determine transfection efﬁ-
ciency of expression plasmids, cells were co-transfected with
pMAX vector (Amaxa Biosystems, Braunschweig, Germany) which
encodes GFP along with the expression plasmids. The ﬂuorescent
signal was measured by analysis on a FACSCalibur (Becton
Dickson, Fair View Lakes, NJ) ﬂow cytometer. pNLENG1-EGP is a
full length infectious molecular clone of HIV-1 containing
enhanced green ﬂuorescent protein(EGFP) between the env and
nef genes. This was kindly provided by D.N. Levy (NYU).ELISA
Virus released from infected cells was quantiﬁed using a
standard Enzyme-Linked Immunosorbent Assay (ELISA) to mea-
sure viral p24 antigen in supernatants (sensitivity 50–200 pg/ml)
(Liao et al., 2003). Absorbance was measured on a Fluorstar
Optima plate reader (BMG Labtech).Western blot
Protein analysis was accomplished using the NuPAGE gel
electrophoresis system (Invitrogen, Carlsbad, CA). Cells were
lysed on ice for 30 min in RIPA buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and
protease inhibitors (Roche)). Lysates were clariﬁed at 16,000 g
at 4 1C. Protein lysates were resolved on 10% Bis-Tris gels, and
then transferred onto nitrocellulose using a semi-dry transfer
apparatus (Bio-Rad). Membranes were blocked for 1 h in 5% non-
fat milk in PBS, followed by 3 washes in PBST (PBS, 0.5% Tween-
20) before probing with primary antibodies. Membranes were
then incubated with secondary antibodies conjugated to perox-
idase. Chemiluminiscent substrate (ECL, GE Healthcare Life
Sciences) was used for detection.Immunoprecipitation
Cells were ﬁrst pelleted at 1000 g for 5 min and resuspended
in NP-40 lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1%
NP-40, 2 mM EDTA, and protease inhibitors (Roche) then incu-
bated on ice for 30 min. Lysates were clariﬁed by centrifugation at
16,000 g for 20 min at 4 1C. Immunoprecipitation were per-
formed using 500 mg of total protein and 10 mg/mL of either anti-
myc mAb (9E10 clone) or anti-acetyl-lysine polyclonal antibodies.
Samples were incubated on ice O/N and immune complexes were
recovered by adding protein A/G sepharose for 1 h at 4 1C. Beads
were washed twice with lysis buffer and resuspended in loading
buffer and prepared for SDS-PAGE.Antibodies
Antibodies used in this study were polyclonal rabbit anti-
caveolin-1 (BD Transduction Laboratories, cat no. 610059), HIV-1
p24 KC57-FITC and KC57–p24-RD1 (Beckman Coulter, cat nos.
6604665 and 6604667). anti-p65 mAb (Santa Cruz), anti-phos-
pho-p65 (S276; Cell Signaling), anti-IkBa (Cell Signaling), anti-
phospho-IkBa (14D4; Cell Signal), anti-acetyl-lysine antibody
(#9441; Cell Signal). Anti-acetyl-lysine (21623; Abcam), anti-
topoisomerase (clone H-300; Santa Cruz), and anti-RNA polymer-
ase II (Millipore).Flow cytometry
Cells transfected with cDNA for ﬂuorescent-tagged proteins
were pelleted and washed with PBS to remove excess culture
medium. Cells were then ﬁxed with 50 ul of 2% paraformaldehyde
in PBS for 15 min at room temperature. The cells were then
washed using 1 ml of PBS and resuspended in 1ml of FACS buffer
(1XPBS, 5% FCS, and 0.1% sodium azide). The cell suspension was
analyzed by ﬂow cytometry (FACSCalibur, Becton Dickson) for
speciﬁc signals associated with expression of tagged proteins.
Controls consisted of untransfected cells or cells transfected with
empty vector. Protein expression was also assessed by staining
cells with directly-conjugated monoclonal antibodies or untagged
primary antibodies and directly-conjugated secondary antibodies,
followed by ﬂow cytometry analysis.
Cholesterol analysis
Cholesterol content of fractions from sucrose gradients was
measured using the Amplex Red Cholesterol Oxidase kit (Invitro-
gen, Carlsbad, CA). Fractions collected at the completion of lipid
raft isolation were subjected to the cholesterol oxidase assay as
per manufacturer’s protocol. The protein concentration of cell
lysates determined was by BCA assay (Pierce/THERMO). For ﬁlipin
staining, transfected cells were grown on 35 mm glass-bottom
dishes (MatTek Corporation, Ashland, MA) under normal growth
conditions and then ﬁxed in 2% paraformaldehyde in PBS for
15 min. The cells were then incubated on ice with ﬁlipin at 50 mg/
ml in PBS for 30 min. Analysis of ﬁlipin staining was performed
using a Nikon TE2000 wide-ﬁeld microscope (Nikon Instruments,
Melville, NY). All images were acquired with a plan ﬂuor
601.3 NA oil immersion objective equipped with an ultraviolet
ﬁlter. The digital image acquisition was performed with Nikon
Elements Advanced Research Software (Nikon Instruments,
Melville, NY).
Nuclear binding assays
Transfected cells were lysed in nuclear/cytoplasmic extraction
buffer from NE/PER kit (Pierce) per manufacturer’s instructions.
The protein content of nuclear and cytoplasmic lysates was
measured by BCA assay (Pierce). After lysis aliquots were placed
at 80 1C until use. An equal amount of protein equivalents were
placed into wells containing oligonucleotides with kB binding
sites provided with NF-kB p65 Transcription Factor Assay Kit
(Pierce/THERMO). Lysates were incubated in the wells for 1 h
before washing the plates with provided wash buffer. Next
primary antibodies (anti-p65, dilution 1:1000), were added to
each well and incubated at room temperature for 1 h, followed by
an additional wash step. Finally secondary antibody was added
(horseradish peroxidase-conjugated, 1:10000), and incubated for
1 h at room temperature. After a ﬁnal wash, luminal detection
solution was added to the well for 20 min. Chemiluminiscent
signal was detected on ﬂuorescent plate reader.
Electrophoretic mobility shift assay
Nuclear extracts were obtained as described above. Extracts
were thawed and added to binding reactions. Nuclear extract
volumes were used between 0.5 and 4.0 ul with 20 fmol of either
wild type HIV-1 LTR-biotinylated probe (Biotin-50-TACAAGG-
GACTTTCCGCTGGGGACTTTCCAGGGA-30) or mutant probe (Bio-
tin-50-TACAAGCCACTTTCCGCTGGCCACTTTCCAGGGA-30) contain-
ing point mutations in the NF-kB binding sites in ﬁnal volume
of 20 ul. Reaction mix incubated on ice for 30 min. Pre-run 5%
native polyacrylamide in 0.5X TBE at 120 V for 30 min in a
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to each reaction and load onto gel. Run gel at 100 V until dye front
runs 2/3 down the gel at 4 1C. Transfer gel on to a nylon
membrane in 0.5X TBE for 30 min at 400 mA for 30 min (at
constant 25 V). Crosslink membrane with a UV crosslinker. Probes
detected as described by LightShift Chemiluminescent EMSA kit
protocol (Pierce/THERMO).
Statistical analysis
All experiments were reproduced two to four times, and
representative experiments are shown. The average of repeat
experiments was plotted and the standard deviation of mean
was calculated from experimental values. The student t test was
used to determine statistical signiﬁcance of the differences.Acknowledgments
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